--- title: "Moderna 被《時代》雜誌評選為全球最具影響力的公司之一" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/286159154.md" description: "Moderna, Inc. 在《時代》雜誌 2026 年全球最具影響力公司榜單中排名第一，表彰其在 mRNA 技術方面的開創性工作。首席執行官 Stéphane Bancel 強調了公司對創新藥物和疫情應對的承諾。在 2026 年，Moderna 獲得了歐洲對其流感加 COVID 組合疫苗 mCOMBRIAX®的批准。該公司繼續擴大合作伙伴關係，並投資於其 mRNA Access 項目，以支持針對新興疾病的研究。該排名基於一種科學方法，評估公司在各個維度上的淨積極貢獻" datetime: "2026-05-12T21:11:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286159154.md) - [en](https://longbridge.com/en/news/286159154.md) - [zh-HK](https://longbridge.com/zh-HK/news/286159154.md) --- # Moderna 被《時代》雜誌評選為全球最具影響力的公司之一 **CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 /** Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on _TIME_'s 2026 list of the World's Most Impactful Companies. The recognition highlights the Company's work as a pioneer of mRNA technology and its focus on delivering meaningful benefits for patients and society. "We are honored to be recognized by _TIME_ as one of the world's most impactful companies," said Stéphane Bancel, Chief Executive Officer of Moderna. "This reflects the dedication of our team to our mission and advancing mRNA science for patients. We remain focused on developing innovative medicines to address significant unmet needs, expanding the reach of our platform across infectious diseases, oncology and rare diseases, and strengthening pandemic preparedness to deliver lasting impact for people and communities around the world." In 2026, Moderna received approval in Europe for its fourth product, mCOMBRIAX®, a flu plus COVID combination vaccine. As its product portfolio grows, the Company continues to invest in its long-term strategic partnerships with the United Kingdom, Canada and Australia to support pandemic readiness by expanding manufacturing capacity and minimizing response times. Moderna recently marked the fourth anniversary of the Moderna Charitable Foundation and published its fourth annual Impacting Human Health Report. Through its mRNA Access program, the Company partners with the scientific community to offer researchers the use of its mRNA technology to explore new vaccines against emerging or neglected infectious diseases. Since its launch in 2022, the program has grown to include 35 institutions worldwide. Presented by _TIME_ and Statista, this ranking is grounded in a science-based methodology. The Upright Project's Net Impact Model evaluates companies based on the net-positive contributions of their products and services across four key dimensions: Society, Knowledge, Health, and Environment, which are measured throughout the full value chain and comparable across industries and regions. For the complete feature along with individual company rankings, please visit time.com. **About Moderna** Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn. **Moderna Contacts** Media: Chris Ridley Vice President, Global Head of Communications +1 617-800-3651 Chris.Ridley@modernatx.com Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 Lavina.Talukdar@modernatx.com **SOURCE:** Moderna, Inc. View the original press release on ACCESS Newswire ### 相關股票 - [MRNA.US](https://longbridge.com/zh-HK/quote/MRNA.US.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [.NDX.US](https://longbridge.com/zh-HK/quote/.NDX.US.md) - [ACCS.US](https://longbridge.com/zh-HK/quote/ACCS.US.md) ## 相關資訊與研究 - [在流感疫苗數據公佈以及漢坦病毒項目引起關注後，評估 Moderna（MRNA）的估值](https://longbridge.com/zh-HK/news/286642428.md) - [巨生醫獲 SelectUSA 醫療科技組金牌 啟動美國 A 輪募資目標 1000 萬美元](https://longbridge.com/zh-HK/news/286905054.md) - [漢坦病毒：是否有再次爆發大流行病的風險？](https://longbridge.com/zh-HK/news/286634066.md) - [ADHD 用藥「利他能」缺貨...網友疑考季因素 食藥署：藥廠早通知控貨中](https://longbridge.com/zh-HK/news/286754700.md) - [Bernstein 重申對 Moderna（MRNA）的持有評級](https://longbridge.com/zh-HK/news/286092762.md)